MedClean Technologies and Socius Capital Group enter into preferred stock purchase agreement

MedClean Technologies, Inc. (OTC Bulletin Board: MCLN) today announced the Company has entered into a preferred stock purchase agreement with Socius Capital Group, LLC, a Delaware limited liability company, doing business as Socius Life Sciences Capital Group, LLC. Pursuant to the Purchase Agreement, MedClean will receive up to $7.5 million in capital.

The Company agreed to sell up to 750 shares of its Series C Preferred Stock, in one or more tranches from time to time. The tranches will be sold at the Company's sole discretion, at a purchase price of $10,000 per share, for an aggregate purchase price of up to $7.5 million. With each tranche, Socius will also receive five-year warrants to purchase that number of shares of the Company's common stock equal to 135% of the value of preferred stock delivered in such tranche. The exercise price of such warrants will equal the closing bid price of the Company's common stock on the date the Company provides notice of such tranche.

Pursuant to the Purchase Agreement MedClean will pay a commitment fee to Socius equal to 5% of the total commitment and will use its best efforts to file a registration statement within 30 days with the Securities and Exchange Commission for the resale of all shares of common stock issuable pursuant to the Purchase Agreement.

Scott Grisanti, the Company's Chairman, commented, "This transaction provides MedClean with the capital required to accelerate execution of its growth and expansion strategy. The Company has claimed the leadership role in industry through development and delivery of its MedClean On-Demand Container and Mobile solutions, which are based on significant intellectual property. The Socius investment vehicle provides the means to expand delivery of MedClean's solutions to a broader customer base through a variety of system acquisition options and additional distribution channels and partners. Also, the investment will enable MedClean to accelerate development plans for new product lines that target new market segments, especially the non-hospital small quantity generator market for regulated medical waste treatment."

David Laky, MedClean's President and CEO commented, "The company's environmentally friendly technology for regulated medical waste disposal and confidential document destruction represents a compelling opportunity for large and small hospitals and medical centers, particularly in light of the current administration's health care cost-cutting focus and escalating concerns by the justice department indicating the need for alternate solutions for medical waste disposal."

Source:

MedClean Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.